Mabwell Bioscience-B (02493): To present 9MW2821 clinical data as an oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress

Zhitong Finance APP news, Mabwell Biotech-B (02493) announced that the company will present, in an oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress held in Madrid, Spain, from October 23 to October 27, 2026, Phase II clinical study data of its innovative Nectin-4-targeting ADC drug for patients with locally advanced or metastatic triple-negative breast cancer (TNBC) who have previously received treatment with an ADC payload based on a topoisomerase I inhibitor: